Fenofibrate insulates diacylglycerol in lipid droplet/ER and preserves insulin signaling transduction in the liver of high fat fed mice

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1852, Issue 7, 2015, Pages 1511-1519

  Chan, Stanley M H ^a   Zeng, Xiao Yi ^a   Sun, Ruo Qiong ^a   Jo, Eunjung ^a   Zhou, Xiu ^a   Wang, Hao ^a   Li, Songpei ^a   Xu, Aimin ^b   Watt, Matthew J ^c   Ye, Ji Ming ^a  

^a RMIT UNIVERSITY   (Australia)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c MONASH UNIVERSITY   (Australia)

Author keywords

DAG repartitioning; FA oxidation; FA synthesis; Insulin signaling; PPAR

Indexed keywords

DIACYLGLYCEROL; FAT DROPLET; FENOFIBRATE; GLUCOSE; INSULIN; DIGLYCERIDES; HYPOLIPIDEMIC AGENTS; LIPID DROPLETS; PPAR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY MASS; CELL MEMBRANE; CONTROLLED STUDY; FAT INTAKE; FATTY LIVER; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE; INSULIN RESISTANCE; INTRACELLULAR SPACE; LIPID DIET; LIPID LIVER LEVEL; LIVER PROTECTION; LUNG GAS EXCHANGE; MALE; METABOLIC SYNDROME X; MOUSE; NONHUMAN; OXIDATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; RADIOIMMUNOASSAY; SIGNAL TRANSDUCTION; WEIGHT GAIN; WESTERN BLOTTING; ADVERSE EFFECTS; ANIMALS; DIET, HIGH-FAT; DRUG EFFECTS; ENDOPLASMIC RETICULUM; LIVER; METABOLISM; MICE; MICE, INBRED C57BL; PATHOLOGY;

MUS;

ANIMALS; DIET, HIGH-FAT; DIGLYCERIDES; ENDOPLASMIC RETICULUM; FATTY LIVER; FENOFIBRATE; HYPOLIPIDEMIC AGENTS; INSULIN; LIPID DROPLETS; LIVER; MALE; MICE; MICE, INBRED C57BL; PPAR ALPHA; SIGNAL TRANSDUCTION;

EID: 84928723655     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2015.04.005     Document Type: Article

References (40)

1. Samuel V.T., Petersen K.F., Shulman G.I. Lipid-induced insulin resistance: unravelling the mechanism. Lancet 2010, 375:2267-2277.
2. Gaggini M., Morelli M., Buzzigoli E., DeFronzo R.A., Bugianesi E., Gastaldelli A. Non-alcoholic fatty liver disease and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients 2013, 5:1544-1560.
3. Turner N., Kowalski G.M., Leslie S.J., Risis S., Yang C., Lee-Young R.S., et al. Distinct patterns of tissue-specific lipid accumulation during the induction of insulin resistance in mice by high-fat feeding. Diabetologia 2013, 56:1638-1648.
4. Stefan N., Haring H.U. The role of hepatokines in metabolism. Nat. Rev. Endocrinol. 2013, 9:144-152.
5. Kumashiro N., Erion D.M., Zhang D., Kahn M., Beddow S.A., Chu X., et al. Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:16381-16385.
6. Benhamed F., Denechaud P.D., Lemoine M., Robichon C., Moldes M., Bertrand-Michel J., et al. The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans. J. Clin. Invest. 2012, 122:2176-2194.
7. Samuel V.T., Liu Z.X., Qu X., Elder B.D., Bilz S., Befroy D., et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J. Biol. Chem. 2004, 279:32345-32353.
8. Jornayvaz F.R., Shulman G.I. Diacylglycerol activation of protein kinase C epsilon and hepatic insulin resistance. Cell Metab. 2012, 15:574-584.
9. Brown J.M., Betters J.L., Lord C., Ma Y., Han X., Yang K., et al. CGI-58 knockdown in mice causes hepatic steatosis but prevents diet-induced obesity and glucose intolerance. J. Lipid Res. 2010, 51:3306-3315.
10. Sun Z., Miller R.A., Patel R.T., Chen J., Dhir R., Wang H., et al. Hepatic Hdac3 promotes gluconeogenesis by repressing lipid synthesis and sequestration. Nat. Med. 2012, 18:934-942.
11. Monetti M., Levin M.C., Watt M.J., Sajan M.P., Marmor S., Hubbard B.K., et al. Dissociation of hepatic steatosis and insulin resistance in mice overexpressing DGAT in the liver. Cell Metab. 2007, 6:69-78.
12. Cantley J.L., Yoshimura T., Camporez J.P., Zhang D., Jornayvaz F.R., Kumashiro N., et al. CGI-58 knockdown sequesters diacylglycerols in lipid droplets/ER-preventing diacylglycerol-mediated hepatic insulin resistance. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:1869-1874.
13. Schmitz-Peiffer C., Biden T.J. Protein kinase C function in muscle, liver, and beta-cells and its therapeutic implications for type 2 diabetes. Diabetes 2008, 57:1774-1783.
14. Chan S.M., Sun R.Q., Zeng X.Y., Choong Z.H., Wang H., Watt M.J., et al. Activation of PPARalpha ameliorates hepatic insulin resistance and steatosis in high fructose-fed mice despite increased ER stress. Diabetes 2013, 62:2095-2105.
15. Stanhope K.L., Schwarz J.M., Keim N.L., Griffen S.C., Bremer A.A., Graham J.L., et al. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J. Clin. Invest. 2009, 119:1322-1334.
16. Ren L.P., Chan S.M., Zeng X.Y., Laybutt D.R., Iseli T.J., Sun R.Q., et al. Differing endoplasmic reticulum stress response to excess lipogenesis versus lipid oversupply in relation to hepatic steatosis and insulin resistance. PLoS One 2012, 7:e30816.
17. Tan M.J., Ye J.M., Turner N., Hohnen-Behrens C., Ke C.Q., Tang C.P., et al. Antidiabetic activities of triterpenoids isolated from bitter melon associated with activation of the AMPK pathway. Chem. Biol. 2008, 15:263-273.
18. Lee A.H., Scapa E.F., Cohen D.E., Glimcher L.H. Regulation of hepatic lipogenesis by the transcription factor XBP1. Science 2008, 320:1492-1496.
19. Oosterveer M.H., Grefhorst A., van Dijk T.H., Havinga R., Staels B., Kuipers F., et al. Fenofibrate simultaneously induces hepatic fatty acid oxidation, synthesis, and elongation in mice. J. Biol. Chem. 2009, 284:34036-34044.
20. Inagaki T., Dutchak P., Zhao G., Ding X., Gautron L., Parameswara V., et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab. 2007, 5:415-425.
21. Samuel V.T., Shulman G.I. Mechanisms for insulin resistance: common threads and missing links. Cell 2012, 148:852-871.
22. Koh K.K., Quon M.J., Shin K.C., Lim S., Lee Y., Sakuma I., et al. Significant differential effects of omega-3 fatty acids and fenofibrate in patients with hypertriglyceridemia. Atherosclerosis 2012, 220:537-544.
23. Shin S.J., Lim J.H., Chung S., Youn D.Y., Chung H.W., Kim H.W., et al. Peroxisome proliferator-activated receptor-alpha activator fenofibrate prevents high-fat diet-induced renal lipotoxicity in spontaneously hypertensive rats. Hypertens. Res. 2009, 32:835-845.
24. Sekiya M., Yahagi N., Matsuzaka T., Najima Y., Nakakuki M., Nagai R., et al. Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression. Hepatology 2003, 38:1529-1539.
25. Reddy J.K., Rao M.S. Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. Am. J. Physiol. Gastrointest. Liver Physiol. 2006, 290:G852-G858.
26. Donnelly K.L., Smith C.I., Schwarzenberg S.J., Jessurun J., Boldt M.D., Parks E.J. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Invest. 2005, 115:1343-1351.
27. Cooney G.J., Thompson A.L., Furler S.M., Ye J., Kraegen E.W. Muscle long-chain acyl CoA esters and insulin resistance. Ann. N. Y. Acad. Sci. 2002, 967:196-207.
28. Holland W.L., Brozinick J.T., Wang L.P., Hawkins E.D., Sargent K.M., Liu Y., et al. Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. Cell Metab. 2007, 5:167-179.
29. Kim J.K., Fillmore J.J., Chen Y., Yu C., Moore I.K., Pypaert M., et al. Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:7522-7527.
30. Wiedemann M.S., Wueest S., Item F., Schoenle E.J., Konrad D. Adipose tissue inflammation contributes to short-term high-fat diet-induced hepatic insulin resistance. Am. J. Physiol. Endocrinol. Metab. 2013, 305:E388-E395.
31. Wang X.A., Zhang R., She Z.G., Zhang X.F., Jiang D.S., Wang T., et al. Interferon regulatory factor 3 constrains IKKbeta/NF-kappaB signaling to alleviate hepatic steatosis and insulin resistance. Hepatology 2014, 59:870-885.
32. Pawlak M., Bauge E., Bourguet W., De Bosscher K., Lalloyer F., Tailleux A., et al. The transrepressive activity of peroxisome proliferator-activated receptor alpha is necessary and sufficient to prevent liver fibrosis in mice. Hepatology 2014, 60:1593-1606.
33. Pedersen D., Schmitz-Peiffer C. The role of protein kinase C epsilon in the regulation of insulin receptor trafficking and insulin action. Diabetes 2010, 59:A383-A.
34. Samuel V.T., Liu Z.X., Wang A., Beddow S.A., Geisler J.G., Kahn M., et al. Inhibition of protein kinase C epsilon prevents hepatic insulin resistance in nonalcoholic fatty liver disease. J. Clin. Invest. 2007, 117:739-745.
35. Rakhshandehroo M., Sanderson L.M., Matilainen M., Stienstra R., Carlberg C., de Groot P.J., et al. Comprehensive analysis of PPARalpha-dependent regulation of hepatic lipid metabolism by expression profiling. PPAR Res. 2007, 2007:26839.
36. Kersten S. Integrated physiology and systems biology of PPARalpha. Mol Metab. 2014, 3:354-371.
37. Kuerschner L., Moessinger C., Thiele C. Imaging of lipid biosynthesis: how a neutral lipid enters lipid droplets. Traffic 2008, 9:338-352.
38. Shi Y., Burn P. Lipid metabolic enzymes: emerging drug targets for the treatment of obesity. Nat. Rev. Drug Discov. 2004, 3:695-710.
39. Waterman I.J., Zammit V.A. Differential effects of fenofibrate or simvastatin treatment of rats on hepatic microsomal overt and latent diacylglycerol acyltransferase activities. Diabetes 2002, 51:1708-1713.
40. Waterman I.J., Zammit V.A. Activities of overt and latent diacylglycerol acyltransferases (DGATs I and II) in liver microsomes of ob/ob mice. Int. J. Obes. Relat. Metab. Disord. 2002, 26:742-743.